Melanoma
Advaced or metastatic BRAF V600E/K mutation positive melanoma.
A phase III randomized, open -label study comparing GSK1120212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation positive melanoma.
- Study phase III
Melanoma with measurable metastatic disease
A phase I/II study of active immunotherapy with autologus dendritic cells either pulsed with Mage-3.A1 or electroporated with Mage-3 encoding mRNA in cutaneous melanoma patients with measurable metastatic disease .
- Study Phase I/II
- Selection criteria
Stage III or IV melanoma
A phase I study on the safety and immunogenicity of combined interdermal and intravenous administration of an autologous mRNA electroporated dendritic cell vaccine in patients with previously treated unresectable stage III or IV melanoma.
-
Study phase I
Metastatic and/or inoperable melanoma
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Randomized, Phase III, Open Label, Multi-center, Two-arm Study to Compare the Efficacy of Tasigna ® Versus Dacarbazine (DTIC) in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
-
Study phase III